Device Trial Radar · NCT00793013
Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation
Last checked: Nov 20, 2026Latest source record: Nov 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Nov 2, 2020
Primary completion
Nov 2, 2020
Study completion Nov 2, 2020
Sponsor
- Lead sponsor
- University of Tennessee, ChattanoogaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Traditional modes of ventilation have failed to improve patient survival. Subsequent observations that elevated airway pressures observed in traditional forms of ventilation resulted in barotrauma and extension of ALI lead to the evolution of low volume cycled ventilation as a potentially better ventilatory modality for ARDS. Recent multicenter trials by the NIH-ARDS network have confirmed that low volume ventilation increases the number of ventilatory free days and improves overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, and decreases the risk of oxygen toxicity. Airway pressure release ventilation (APRV) is a novel ventilatory modality that utilizes controlled positive airway pressure to maximize alveolar recruitment while minimizing barotrauma. In APRV, tidal ventilation occurs between the increase in lung volumes established by the application of CPAP and the relaxation of lung tissue following pressure release. Preliminary studies have suggested that APRV recruits collapsed alveoli and improves oxygenation through a restoration of pulmonary mechanics, but there are no studies indicating the potential overall benefit of APRV in recovery form ALI/ADRS.
Conditions
- Acute Lung Injury
- Adult Respiratory Distress Syndrome
- Kidney Injury
Interventions
Volume-Cycled Assist-Control (AC) modeDevice
1. Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 \< 40% 2. Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min 3. Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg \& setting positive end-expiratory pressure (PEEP) based on level of initial FiO2 4. Inspiratory to Expiratory ratio set at 1:1 to 1:3 5. If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased 6. Mgmt of PEEP will be conducted as per the ARDSnet Protocol 7. Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95% 8. Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol
Airway Pressure Release Ventilation (APRV) modeDevice
1. Ventilation uses Drager Model X1 2. Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels 3. Time periods for the high \& low pressure levels can be set independently 4. Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume 5. Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min 6. Spontaneous frequency will be targeted for 6 to 18 breaths/per min 7. If spontaneous breathing is achieved,level of sedation will be decreased 8. If spontaneous respirations are \>20 breaths/min, sedation will be increased 9. If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased
Primary outcomes
What the sponsor says the trial is designed to measure.
- All cause mortalityTime frame: 28 days or prior to hospital discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
James A. Tumlin, MD
Chattanooga, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.